Matches in SemOpenAlex for { <https://semopenalex.org/work/W2959093666> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2959093666 endingPage "10972" @default.
- W2959093666 startingPage "10966" @default.
- W2959093666 abstract "Vorapaxar-dependent protease-activated receptor (PAR)-1 inhibition diminishes diabetic nephropathy in experimental type 1 diabetes. As most patients with diabetic nephropathy suffer from type 2 diabetes, the aim of this study was to investigate whether PAR-1 inhibition also limits diabetic nephropathy in experimental type 2 diabetes. Consequently, leptin-deficient black and tan brachyuric (BTBRob/ob) mice were randomly assigned to vorapaxar (1.75 mg/kg; twice weekly via oral gavage) or vehicle treatment, whereas matched wild-type (WT) BTBR (BTBRWT) mice served as nondiabetic controls. Weight and (nonfasting) blood glucose levels were monitored for up to 18 wk, after which kidney function and histologic damage was evaluated postmortem. We show that blood glucose levels and body weight increased in diabetic BTBRob/ob mice compared with nondiabetic BTBRWT controls. Vorapaxar-dependent PAR-1 inhibition reduced but did not normalize blood glucose levels in BTBRob/ob mice, whereas it potentiated the increase in body weight. Vorapaxar did not, however, preserve kidney function, whereas it only minimally reduced histopathological signs of kidney injury. Overall, we thus show that PAR-1 inhibition reduces blood glucose levels during the progression of diabetic nephropathy in experimental type 2 diabetes but does not improve renal function. This is in contrast to the therapeutic potential of vorapaxar in type 1 diabetes-induced nephropathy, highlighting the importance of disease-dependent treatment modalities.-Waasdorp, M., Florquin, S., Duitman, J., Spek, C. A. Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy." @default.
- W2959093666 created "2019-07-23" @default.
- W2959093666 creator A5034585119 @default.
- W2959093666 creator A5036345568 @default.
- W2959093666 creator A5050066950 @default.
- W2959093666 creator A5083659210 @default.
- W2959093666 date "2019-07-09" @default.
- W2959093666 modified "2023-09-26" @default.
- W2959093666 title "Pharmacological PAR‐1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy" @default.
- W2959093666 cites W1988966858 @default.
- W2959093666 cites W2024567012 @default.
- W2959093666 cites W2073281165 @default.
- W2959093666 cites W2075837574 @default.
- W2959093666 cites W2114598208 @default.
- W2959093666 cites W2121697764 @default.
- W2959093666 cites W2134322421 @default.
- W2959093666 cites W2400520418 @default.
- W2959093666 cites W2521011435 @default.
- W2959093666 cites W2567958607 @default.
- W2959093666 cites W2588236173 @default.
- W2959093666 cites W2598844163 @default.
- W2959093666 cites W2606390009 @default.
- W2959093666 cites W2739353751 @default.
- W2959093666 cites W2754072852 @default.
- W2959093666 cites W2800995050 @default.
- W2959093666 doi "https://doi.org/10.1096/fj.201900516r" @default.
- W2959093666 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31287960" @default.
- W2959093666 hasPublicationYear "2019" @default.
- W2959093666 type Work @default.
- W2959093666 sameAs 2959093666 @default.
- W2959093666 citedByCount "6" @default.
- W2959093666 countsByYear W29590936662020 @default.
- W2959093666 countsByYear W29590936662022 @default.
- W2959093666 countsByYear W29590936662023 @default.
- W2959093666 crossrefType "journal-article" @default.
- W2959093666 hasAuthorship W2959093666A5034585119 @default.
- W2959093666 hasAuthorship W2959093666A5036345568 @default.
- W2959093666 hasAuthorship W2959093666A5050066950 @default.
- W2959093666 hasAuthorship W2959093666A5083659210 @default.
- W2959093666 hasConcept C126322002 @default.
- W2959093666 hasConcept C134018914 @default.
- W2959093666 hasConcept C159641895 @default.
- W2959093666 hasConcept C2777180221 @default.
- W2959093666 hasConcept C2778653478 @default.
- W2959093666 hasConcept C2779922275 @default.
- W2959093666 hasConcept C2780091579 @default.
- W2959093666 hasConcept C2781184683 @default.
- W2959093666 hasConcept C555293320 @default.
- W2959093666 hasConcept C71924100 @default.
- W2959093666 hasConceptScore W2959093666C126322002 @default.
- W2959093666 hasConceptScore W2959093666C134018914 @default.
- W2959093666 hasConceptScore W2959093666C159641895 @default.
- W2959093666 hasConceptScore W2959093666C2777180221 @default.
- W2959093666 hasConceptScore W2959093666C2778653478 @default.
- W2959093666 hasConceptScore W2959093666C2779922275 @default.
- W2959093666 hasConceptScore W2959093666C2780091579 @default.
- W2959093666 hasConceptScore W2959093666C2781184683 @default.
- W2959093666 hasConceptScore W2959093666C555293320 @default.
- W2959093666 hasConceptScore W2959093666C71924100 @default.
- W2959093666 hasFunder F4320321708 @default.
- W2959093666 hasIssue "10" @default.
- W2959093666 hasLocation W29590936661 @default.
- W2959093666 hasLocation W29590936662 @default.
- W2959093666 hasOpenAccess W2959093666 @default.
- W2959093666 hasPrimaryLocation W29590936661 @default.
- W2959093666 hasRelatedWork W146232960 @default.
- W2959093666 hasRelatedWork W1563850031 @default.
- W2959093666 hasRelatedWork W1980339709 @default.
- W2959093666 hasRelatedWork W2038405492 @default.
- W2959093666 hasRelatedWork W2038657938 @default.
- W2959093666 hasRelatedWork W2127085070 @default.
- W2959093666 hasRelatedWork W2149729817 @default.
- W2959093666 hasRelatedWork W2357968536 @default.
- W2959093666 hasRelatedWork W3174003962 @default.
- W2959093666 hasRelatedWork W1720298151 @default.
- W2959093666 hasVolume "33" @default.
- W2959093666 isParatext "false" @default.
- W2959093666 isRetracted "false" @default.
- W2959093666 magId "2959093666" @default.
- W2959093666 workType "article" @default.